Synthesis of 6-chloro-2-Aryl-1H-imidazo[4,5-b]pyridine derivatives: Antidiabetic, antioxidant, β-glucuronidase inhibiton and their molecular docking studies.
6-Chloro-2-Aryl-1H-imidazo[4,5-b]pyridine derivatives 1-26 were synthesized and characterized by various spectroscopic techniques. All these derivatives were evaluated for their antiglycation, antioxidant and β-glucuronidase potential followed their docking studies. In antiglycation assay, compound 2 (IC50=240.10±2.50μM) and 4 (IC50=240.30±2.90μM) was found to be most active compound of this series, while compounds 3 (IC50=260.10±2.50μM), 6 (IC50=290.60±3.60μM), 13 (IC50=288.20±3.00μM) and 26 (IC50=292.10±3.20μM) also showed better activities than the standard rutin (IC50=294.50±1.50μM). In antioxidant assay, compound 1 (IC50=69.45±0.25μM), 2 (IC50=58.10±2.50μM), 3 (IC50=74.25±1.10μM), and 4 (IC50=72.50±3.30μM) showed good activities. In β-glucuronidase activity, compounds 3 (IC50=29.25±0.50μM), compound 1 (IC50=30.10±0.60μM) and compound 4 (IC50=46.10±1.10μM) showed a significant activity as compared to than standard D-Saccharic acid 1,4-lactonec (IC50=48.50±1.25μM) and their interaction with the enzyme was confirm by docking studies.
['Taha|Muhammad|M|', 'Ismail|Nor Hadiani|NH|', 'Imran|Syahrul|S|', 'Rashwan|Hesham|H|', 'Jamil|Waqas|W|', 'Ali|Sajjad|S|', 'Kashif|Syed Muhammad|SM|', 'Rahim|Fazal|F|', 'Salar|Uzma|U|', 'Khan|Khalid Mohammed|KM|']
D000975:Antioxidants D003924:Diabetes Mellitus, Type 2 D004305:Dose-Response Relationship, Drug D005966:Glucuronidase D006023:Glycoproteins D006801:Humans D007004:Hypoglycemic Agents D062105:Molecular Docking Simulation D015394:Molecular Structure D011687:Purines D013329:Structure-Activity Relationship
β-Glucuronidase Antiglycation 6-Chloro-2-Aryl-1H-imidazo[4, 5-b]pyridine Anti-oxidant Spectroscopy